Levetiracetam in the treatment of pediatric headache

Efficacy and safety of levetiracetam for migraine prophylaxis: A systematic review

“…18 Six of the 11 studies included patients who had previously tried and failed, or were unable to tolerate, at least one other medication used for migraine prophylaxis. 19,21,26 The response rates and reduction in headache frequency and severity appear to be similar in these studies, when compared to the five studies that only included prophy- Based on available data, levetiracetam seems to be best tolerated by adults between 18 and 60 years old. 19,21,26 The response rates and reduction in headache frequency and severity appear to be similar in these studies, when compared to the five studies that only included prophy- Based on available data, levetiracetam seems to be best tolerated by adults between 18 and 60 years old.…”

“…In studies which evaluated per cent of responders (ie, ≥ 50% decrease in migraine frequency), 57.9%-100% of patients on levetiracetam were classified as responders [19][20][21][22][23][24] while previous studies found that 25 Overall, levetiracetam appears to have similar efficacy in episodic migraine prophylaxis as seen with AEDs currently FDAapproved for migraine prophylaxis and has demonstrated benefit in patients with chronic migraine. In studies which evaluated per cent of responders (ie, ≥ 50% decrease in migraine frequency), 57.9%-100% of patients on levetiracetam were classified as responders [19][20][21][22][23][24] while previous studies found that 25 Overall, levetiracetam appears to have similar efficacy in episodic migraine prophylaxis as seen with AEDs currently FDAapproved for migraine prophylaxis and has demonstrated benefit in patients with chronic migraine.…”

“…While 2 studies showed statistically significant improvement in headache frequency after 1 month of treatment, 21,26 the studies in which patients were treated for 2-6 months showed that response rates continued to improve and outcomes were more likely to significantly differ from the comparator when treated for at least 2 months. 18,19,21,23,26,27 Of these, 3 studies included only patients who had trialled other medications for migraine prophylaxis. 18,19,21,23,26,27 Of these, 3 studies included only patients who had trialled other medications for migraine prophylaxis.…”

“…[18][19][20][21][22][23][24][25][26][27][28] Only 4 of the 11 studies were randomized controlled trials, 23,24,27,28 and only two of those had an active comparator. [18][19][20][21][22][23][24][25][26][27][28] Only 4 of the 11 studies were randomized controlled trials, 23,24,27,28 and only two of those had an active comparator.…”

“… [21][22][23][24][25][26][27][28]. In general, 1000 mg/d has been effective in reducing the occurrence of migraine [18][19][20][21][22][23]25. It also has the advantage of being simple, while the dosage can rapidly be escalated to 1000 mg/d.…”